News headlines about CytomX Therapeutics (NASDAQ:CTMX) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.0457270551161 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s analysis:
- Brokerages Expect CytomX Therapeutics, Inc. (CTMX) Will Post Quarterly Sales of $10.70 Million (americanbankingnews.com)
- Peninsula drug maker’s Son of Yervoy dares cancer to pull off its mask (bizjournals.com)
- CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Other Events (4-traders.com)
- CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic (finance.yahoo.com)
- -$0.39 Earnings Per Share Expected for CytomX Therapeutics, Inc. (CTMX) This Quarter (americanbankingnews.com)
Several brokerages recently commented on CTMX. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Cantor Fitzgerald began coverage on CytomX Therapeutics in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price target on the stock. Cowen reiterated an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. Finally, Oppenheimer reiterated a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $31.88.
In other news, Director Frederick W. Gluck sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $17.30, for a total value of $86,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Robert I. Tepper sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $18.00, for a total value of $360,000.00. Following the completion of the transaction, the insider now owns 54,293 shares in the company, valued at approximately $977,274. The disclosure for this sale can be found here. In the last quarter, insiders sold 156,169 shares of company stock worth $3,488,563. Corporate insiders own 4.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “CytomX Therapeutics (CTMX) Receives Daily News Impact Score of 0.16” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/03/cytomx-therapeutics-ctmx-receives-daily-news-impact-score-of-0-16.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
What are top analysts saying about CytomX Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CytomX Therapeutics Inc. and related companies.